Dermatological Assessment of Photoallergy and Phototoxicity

Inclusion Criteria: * Agreement to comply with safety guidelines to minimize the risk of contamination to COVID-19; * Agreement to perform a molecular test for the detection of COVID-19 to enter the study; * Healthy participants; * Non-injured skin in the test region; * Agreement to adhere to the test procedures and requirements and to attend the institute on the day(s) and at the time(s) determined for the evaluations; * Ability to consent to participation in the study; * Age from 18 to 70 years; * Phototype (Fitzpatrick): II and III; * Any gender Exclusion Criteria: * Participants who belong to the risk group for COVID-19, that is, with diabetes, with chronic cardiovascular, renal and respiratory problems, immunosuppressed or other conditions that the physician deems as belonging to the risk group; * Skin marks in the experimental area; * Active dermatoses (local or widespread); * Pregnant or breastfeeding women; * History of allergic reactions, irritation or intense feelings of discomfort to topical products; * History of phototoxic or photoallergic reactions; * History of allergy to materials used in the study; * History of atopy; * Personal or family pathological history of skin cancer; * History of pathologies aggravated or triggered by ultraviolet radiation; * Carriers of immunodeficiencies; * Intense sun exposure or tanning session up to 15 days before the initial evaluation; * Predicted intense sun exposure or tanning session during the course of the study; * Predicted bathing in the sea, pool or bathtub during the study; * Participants who practice water sports; * Dermography; * Use of the following topical or systemic drugs: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs and corticoids up to 2 weeks prior to selection or, considering deposit corticoids, the interval shall be 1 month prior to selection; * Use of topical or systemic photosensitizing drugs; * Treatment with acid vitamin A and/or its derivatives via oral or topical until 1 month before the beginning of the study; * Aesthetic and/or body dermatological treatment until 3 weeks before selection; * Vaccination during the study or until 3 weeks before the study; * Being or having participated in another clinical trial terminated less than 7 days before selection, in case the previous trial is acceptable in use; * Being or having participated in another clinical trial terminated less than 21 days ago, in case the previous trial is compatible or Adverse Reaction investigative; * History of absence of adherence or unwillingness to adhere to the study protocol; * Professionals directly involved in the execution of this protocol and their relatives. * Participants who have COVID-19, or who present symptoms indicative of the disease in the last 14 days. * Any condition not mentioned above that, in the opinion of the investigator, may compromise the evaluation of the study.